ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
Real-time Estimate Cboe BZX  -  01:51 2022-08-18 pm EDT
0.3360 USD   +1.79%
08/17ADAMIS PHARMACEUTICALS : Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 - Form 8-K
PU
08/17ADAMIS PHARMACEUTICALS CORP : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/15Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ADAMIS PHARMACEUTICALS CORP : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)

06/17/2022 | 04:29pm EDT

Item 3.03. Material Modification to Rights of Security Holders.

The information provided under Item 5.03 below of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.03.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal

             Year.



On June 14, 2022, the board of directors (the "Board") of Adamis Pharmaceuticals Corporation (the "Company") approved amendments to the Company's Amended and Restated Bylaws (the "Bylaws"), effective immediately. The amendments, among other things, modified the provisions for determining the presence of a quorum at all meetings of stockholders, to provide that the presence, in person, by remote communication, if applicable, or by proxy, of both (i) the holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote on one or more matters to be voted on at the meeting, and (ii) the holders of at least one-third of all issued and outstanding shares of Common Stock entitled to vote, will constitute a quorum at all meetings of the stockholders for the transaction of business, and to provide that where a separate vote by a class or classes or series is required, except where otherwise provided by law or by the Company's Restated Certificate of Incorporation or the Bylaws, a majority in voting power of the outstanding shares, rather than a majority of the outstanding shares as was provided prior to the amendment, of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Prior to the amendments, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote, would constitute a quorum for the transaction of business. The amendments also provide in the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority in voting power of the shares, rather than by a majority of the shares, represented at the meeting. Prior to the amendments, a meeting could be adjourned either by the chairman of the meeting or by the vote of the holders of a majority of the shares represented at the meeting.

The foregoing brief description of the Company's amended Bylaws is qualified in its entirety by the full text of the Bylaws, as amended, filed as Exhibit 3.1 hereto and incorporated herein by reference.

© Edgar Online, source Glimpses

All news about ADAMIS PHARMACEUTICALS CORPORATION
08/17ADAMIS PHARMACEUTICALS : Meeting adjourned only with respect to reverse stock split propos..
PU
08/17ADAMIS PHARMACEUTICALS CORP : Submission of Matters to a Vote of Security Holders, Other E..
AQ
08/15Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
AQ
08/12Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
AQ
08/10ADAMIS : Q2 Earnings Snapshot
AQ
08/10ADAMIS PHARMACEUTICALS REPORTS SECON : 30 p.m. PT / 4:30 p.m. ET - Form 8-K
PU
08/10TRANSCRIPT : Adamis Pharmaceuticals Corporation, Q2 2022 Earnings Call, Aug 10, 2022
CI
08/10ADAMIS PHARMACEUTICALS CORP Management's Discussion and Analysis of Financial Conditio..
AQ
08/10Earnings Flash (ADMP) ADAMIS PHARMACEUTICALS CORPORATION Reports Q2 Loss $-0.06
MT
08/10Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corpo..
AQ
More news
Financials (USD)
Sales 2022 6,30 M - -
Net income 2022 -22,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,20x
Yield 2022 -
Capitalization 49,5 M 49,5 M -
Capi. / Sales 2022 7,86x
Capi. / Sales 2023 4,34x
Nbr of Employees 15
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,33
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
David J. Marguglio Director & Vice President-Business Development
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Howard C. Birndorf Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION-45.44%50
JOHNSON & JOHNSON-2.04%440 598
ELI LILLY AND COMPANY14.70%301 034
PFIZER, INC.-16.56%276 521
ROCHE HOLDING AG-16.47%273 077
ABBVIE INC.4.46%250 080